JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation fungerp candidate, SCY-247, against a broad panel of fungal pathogens. The analyses were presented by Mahmoud Ghannoum, Ph.D, Professor and Director Center for Medical Mycology, Case Western Reserve Universit
Antimicrobial resistance is a global problem of increasing proportions that we cannot afford to look away from. Our Editorial shines a light on the crisis and ways we can all help to address it.
The invasive forms of these fungal infections can affect people who are severely ill and who have significant underlying immune system-related conditions.